The activity of US Biotech IPOs has steadily increased within the last five years, having registered a record-high in 2020 with EUR 15.0bn raised in 66 IPOs. The situation in Europe draws a different picture, … Read more
Biotech VC financings in Germany and USA have shown the same positive development over the past five years. In 2020, both countries have increased their biotech VC financings compared to the previous year 2019. But … Read more
With 13 out of 15 companies, the largest crossover rounds in Life Sciences since 2016 are clearly dominated by biotech companies. However, the largest crossover financing was raised by the Chinese healthcare services company Ping … Read more
Since 2016, the number of venture capital deals and the total deal volume per year have significantly increased in the Diagnostics sector. In Europe, the deal volume doubled, while the number of deals rose by … Read more
Between 2016 and 2020, the number of Biotech licensing deals between European licensors and Chinese licensees has more than tripled. The largest deal was the agreement between MediGene AG and Cytovant Sciences HK Ltd for … Read more
US Life Sciences venture capital funds raised in 2020 significantly exceed European and Asian funds! The volumes of the 5 largest US Life Sciences venture capital funds raised in 2020 range between EUR 3,963m and … Read more
The top 10 HealthTech M&A deals (by deal size) range from EUR 3.96bn to EUR 667m, with an average deal size of EUR 1.46bn. All top 10 targets were headquartered in the US. The largest … Read more
Top 10 MedTech M&A deals dominated by US targets! The top 10 MedTech M&A deals (by ticket size) range from EUR 22.5bn to EUR 4.1bn, with an average deal size of EUR 11bn. With 9 … Read more
Is the boom around Special Purpose Acquisition Companies (SPAC) currently suffering a cool off? The number of SPAC IPOs as well as the number of new SPACs in the IPO pipeline have significantly declined since … Read more
The Top 10 biotech M&A deals ranking (by ticket size) shows that there have been exceptionally large deals in the biotech sector over the last years. The largest deal was the acquisition of Celgene by Bristol … Read more
